Academic Journal
Q1Progress in Retinal and Eye Research
About Progress in Retinal and Eye Research
Progress in Retinal and Eye Research is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 5.181 and an H-index of 215.
Its listed coverage is 1994-2026 and its research categories include Ophthalmology (Q1); Sensory Systems (Q1). The 2025 dataset reports 63 documents and 2883 citations across the latest three-year reporting window.
Progress in Retinal and Eye Research: Unlocking the Future of Vision Health
The field of retinal and eye research has witnessed remarkable progress over the past decade, revolutionizing the way we diagnose, manage, and treat a wide array of vision disorders. From cutting-edge imaging technologies to gene therapy and artificial intelligence (AI), advancements in ophthalmology are providing new hope to millions affected by vision impairment and blindness.
Innovations in Retinal Imaging
One of the most significant strides in retinal research is the development of advanced imaging techniques. Optical Coherence Tomography (OCT) has become a gold standard in eye care, enabling non-invasive, high-resolution cross-sectional images of the retina. More recently, OCT angiography (OCTA) has emerged as a powerful tool to visualize retinal blood flow without dye injections. These innovations allow earlier and more accurate detection of diseases like diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma.
Gene and Cell Therapies
Breakthroughs in gene therapy have opened new doors for treating inherited retinal diseases. The FDA-approved gene therapy Luxturna has demonstrated success in restoring vision for patients with Leber’s congenital amaurosis, a rare genetic disorder. Researchers are also exploring CRISPR gene editing as a promising strategy to correct faulty genes directly in the eye.
In parallel, stem cell research is showing potential in regenerating damaged retinal cells. Clinical trials are underway to test the safety and efficacy of retinal pigment epithelium (RPE) transplants derived from stem cells, offering new treatment options for conditions like AMD and retinitis pigmentosa.
Artificial Intelligence in Ophthalmology
AI and machine learning are transforming retinal diagnostics. AI algorithms can now analyze retinal images with accuracy comparable to that of trained ophthalmologists. These systems can detect early signs of diseases such as diabetic retinopathy, macular degeneration, and glaucoma, enabling timely interventions that can prevent vision loss.
AI-powered platforms also aid in triaging patients, streamlining clinic workflows, and expanding access to eye care in underserved regions through teleophthalmology.
Personalized Medicine and Drug Delivery
Progress in retinal and eye research is also paving the way for personalized medicine. Researchers are developing targeted therapies tailored to a patient’s genetic profile, improving treatment outcomes and minimizing side effects.
In addition, innovative drug delivery systems—such as sustained-release implants and injectable nano-formulations—are being tested to reduce the burden of frequent eye injections. These advancements enhance patient compliance and quality of life, particularly for those managing chronic conditions like AMD and diabetic macular edema.
Looking Ahead
As the global population ages, the demand for effective and accessible eye care will continue to rise. The ongoing research in retinal and eye health is not only expanding our understanding of complex ocular diseases but also creating transformative treatment modalities.
The future of vision care is bright, driven by interdisciplinary collaborations and relentless innovation. With continued investment and research, the dream of preventing blindness and restoring sight is closer than ever.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope and Progress in Retinal and Eye Research
Retinal and eye research has witnessed groundbreaking advancements in recent years, reshaping our understanding and treatment of various vision disorders. This specialized field of ophthalmology focuses on the structure, function, and diseases of the retina and related ocular components. As global demand for effective vision care grows—especially with aging populations and increased incidence of conditions like diabetic retinopathy and age-related macular degeneration (AMD)—researchers are intensifying efforts to uncover innovative solutions.
Scope of Retinal and Eye Research
The scope of retinal and eye research is extensive and multidisciplinary, involving clinical studies, molecular biology, genetics, imaging technologies, pharmacology, and biomedical engineering. The primary goals include early diagnosis, improved treatments, and ultimately, prevention or reversal of vision loss.
Some major research areas include:
-
Retinal degenerative diseases like AMD and retinitis pigmentosa.
-
Vascular disorders such as diabetic retinopathy and retinal vein occlusion.
-
Inflammatory conditions like uveitis and autoimmune-related eye diseases.
-
Innovations in imaging such as Optical Coherence Tomography (OCT) and fundus autofluorescence.
-
Gene and cell therapies, particularly for inherited retinal diseases.
-
Artificial vision and bionic eyes, which offer hope for individuals with severe visual impairment.
Recent Progress and Innovations
Recent advances in retinal research have revolutionized treatment strategies. One of the most notable developments is the introduction of anti-VEGF therapies for managing AMD and diabetic macular edema. These drugs have significantly improved visual outcomes for millions of patients worldwide.
Gene therapy is another promising frontier. The FDA approval of Luxturna, a gene therapy for RPE65-related retinal dystrophy, marked a historic milestone, paving the way for targeted genetic treatments for other inherited eye disorders.
Stem cell research has shown potential in regenerating damaged retinal tissues. Clinical trials using induced pluripotent stem cells (iPSCs) to treat macular degeneration are underway, and early results are encouraging.
Meanwhile, artificial intelligence (AI) and deep learning are being integrated into retinal imaging diagnostics. AI algorithms can now detect diabetic retinopathy, glaucoma, and AMD from retinal scans with accuracy comparable to human experts. This could greatly enhance early detection, especially in underserved or remote regions.
Future Outlook
The future of retinal and eye research is bright, with ongoing efforts to improve drug delivery systems (such as sustained-release implants), enhance surgical techniques, and develop non-invasive diagnostic tools. Collaboration among scientists, clinicians, and technology experts is crucial to overcoming current limitations and accelerating breakthroughs.
As research continues to evolve, patients will benefit from more personalized and effective treatments, leading to improved quality of life and reduced healthcare burden.
Recent Research Articles
Latest publications matched automatically by ISSN.
Retinal pigment epithelial detachment: Molecular mechanisms, multimodal imaging classification, and clinical management across the spectrum of macular disease
Pasquale Viggiano, Maria Grazia Pignataro, Alba Chiara Termite, Giacomo Boscia et al.
2026-12 · DOI: 10.1016/j.preteyeres.2026.101512Long noncoding RNAs and diabetic retinopathy: Current understanding, future directions and challenges
Renu A. Kowluru, Inderjeet Kaur, Shusheng Wang, Kai Kaarniranta et al.
2026-12 · DOI: 10.1016/j.preteyeres.2026.101511Novel insights into retinoblastoma: From oncogenic circuitry to precision diagnosis and eye-preserving therapies
Min Zhou, Jieling Tang, Xuyang Wen, Jie Yang et al.
2026-12 · DOI: 10.1016/j.preteyeres.2026.101514Ocular Toxoplasmosis in the Immunocompromised Patient
Elke O. KREPS, João M. FURTADO, Justine R. SMITH
2026-09 · DOI: 10.1016/j.preteyeres.2026.101523Myopia and eye disease: From correlation to causation
James Loughman, Mark A. Bullimore, Daniel Ian Flitcroft
2026-09 · DOI: 10.1016/j.preteyeres.2026.101497Retinal manifestations of Alzheimer's Disease: Insights from animal models, clinical detection, and future translation
Xiayin Zhang, Dongli Zhuang, Chunran Lai, Chunwen Zheng et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101504Editorial Board
2026-09 · DOI: 10.1016/s1350-9462(26)00085-6Rethinking aerobic metabolism in retinal rod outer segments: Triple metabolic hypothesis and clinical implications
Richard H.W. Funk, Maurizio Bruschi, Luca Musante, Andrea Amaroli et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101513Accommodative aqueous regulation: A refractive-state-dependent framework linking presbyopia to glaucoma subtypes
Radouil Tzekov, Ramesh Ayyala
2026-09 · DOI: 10.1016/j.preteyeres.2026.101510The perfusion-based model of AMD: Moving towards a unifying hypothesis
Nancy M. Holekamp, Simona Ivanova Ivanova
2026-09 · DOI: 10.1016/j.preteyeres.2026.101507Lactate signaling and lactylation in retina: From physiological Warburg effect to pathological metabolic reprogramming
Xiang Gu, Ai Zhuang, Jiayan Fan, Xuyang Wen et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101509CDHR1-associated retinal degeneration: Clinical phenotypes and therapeutic approaches
Akshay R. Narayan, Peter Charbel Issa, Imran H. Yusuf, Robert E. MacLaren et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101508Transformation of the extracellular matrix during uveal melanoma development, progression, and at the hepatic metastatic niche
Joshua Hattersley, Karen Aughton, Sarah E. Coupland, Helen Kalirai et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101493ICON-PM: International consensus on nomenclature for adult pathologic myopia
Richard F. Spaide, Anita Agarwal, Shih-Jen Chen, Chi Chun Lai et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101495Seeing anew: Mechanisms, outcomes, and challenges in adapting to restored sight via visual prostheses
Katerina Eleonora K. Rassia, Lydia Liapi, John S. Pezaris
2026-09 · DOI: 10.1016/j.preteyeres.2026.101494Exposome for Ocular Diseases: From Exposure Evidence to Causality and Actionable Prevention
Xiaodong Sun, Guanran Zhang, Xinting Feng, Zhe Hong et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101524Drug delivery across the blood-retinal barrier: Biological gateways for posterior segment therapy
Jongwook Kim, Ye Eun Han, Minkyu Kim, Jisu Choe et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101496Vitreoretinal bioadhesives: Translational challenges and innovative perspectives
Seyyedehfatemeh Ghalibafan, Hajirah N. Saeed, Ali R. Djalilian, R.V. Paul Chan et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101506Gap junctions form bridges between bench studies and clinical ophthalmology
Gergely Szarka, Tamás Kovács-Öller, Gyula Hoffmann, Boglárka Balogh et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101505Introducing the blood-tear barrier: Structure, function, and disruption in ocular surface homeostasis
Marlies Gijs, Li Liang, Fleur Goezinne, Yutong Wang et al.
2026-09 · DOI: 10.1016/j.preteyeres.2026.101492Reviews
Community Reviews
Version History
April 20, 2025 at 5:33 am
April 20, 2025